Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferoxamine for Delayed Cerebral Ischemia after Subarachnoid Hemorrhage
NCT02216513Phase 1Terminated
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2014
- Primary completion
- Jun 2015
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of deferoxamine in subarachnoid hemorrhage (SAH), sponsored by Brigham and Women's Hospital. Primary endpoint: Delayed Cerebral Ischemia at 6 weeks. Started Sep 2014; status: terminated.
02
Drugs
deferoxamine
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT02216513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02216513.